Melanoma Cancer Diagnostics Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2018 to 2028

  • Published : Dec-2018
  • Tables : 32
  • Figures : 159
  • Category : Healthcare
  • No. of Pages : 170
  • Report Code : FACT57MR
  • Format : ppt

Key Insights - Melanoma Cancer Diagnostics

Adoption of Artificial Intelligence (AI) for Melanoma Cancer Diagnosis Growing

The adoption of Artificial Intelligence (AI), combined with large image database, is showing promising results in distinguishing malignant from benign moles and other non-cancerous skin conditions.

Researchers in the US, Germany, and France recently conducted a study using artificial intelligence known as deep learning Convolutional Neural Network (CNN). Researchers compared the performance with 58 international dermatologists and found that CNN missed very few melanomas and misdiagnosed benign moles less often than dermatologists. Along with performing image analysis, the network is capable of teaching itself to improve its performance by using a machine learning process.

melanoma cancer diagnostics market drivers and restraints impact analysi...

The process that CNN used in the research is based on an algorithm developed by Google which allows AI to differentiate between thousands of different objects. However, according to some experts, more work and research is necessary to realize the full potential of this technology for skin cancer diagnosis.

Non-Invasive Techniques Show Promising Results in Skin Cancer Diagnostics

Non-invasive skin cancer diagnostics methods are being used on a large scale for skin cancer diagnosis. Although biopsy is considered to be the best way for skin cancer diagnosis, it is leading to a number of complications including infection, scarring, and bleeding. Hence, researchers are focusing on developing less invasive or non-invasive methods for skin cancer diagnosis.

For instance, Pigmented Lesion Assay (PLA) test by DermTech uses sticky adhesive patch to collect skill cells from lesion to diagnose melanoma and clinical trials found that PLA has high sensitivity and very low probability of missing melanoma. Meanwhile, ongoing technological advancements in optical imaging techniques is also resulting in development of new tools in diagnosis and treatment of skin cancer.

melanoma cancer diagnostics market pricing analysis by test type 2017 &...

As a part of non-invasive medical devices and techniques, researchers are focusing on techniques of dermoscopy and advanced non-invasive imaging techniques including optical coherence tomography and reflectance confocal microscopy. Meta-analysis performed in clinical settings demonstrated that dermoscopy has improved diagnostic accuracy of pigmented and non-pigmented lesions. In the near future, physicians would be able to recognize tumor patterns using dermoscopy technique.

Reflectance confocal microscopy that enables real-time examination of skin tumors has been proven as an excellent method for evaluating melanocytic lesions. Using reflectance confocal microscopy, dermatologist may be able to avoid biopsy of benign tumor. Researchers have also developed Speckle-Variance optical coherence tomography (SV-OCT) capable of detecting vascular changes taking place in melanocytic lesions.

Increasing Incidences of Skin Cancer Driving Demand for Melanoma Cancer Diagnostics

According to the World Health Organization (WHO), around 132,000 melanoma skin cancers occur worldwide every year. It is also estimated that about 10% decrease in ozone levels is likely to result in 4,500 melanoma skin cancer cases. There were nearly 300,000 new melanoma of skin cases in 2018, as per the American Institute of Cancer Research.

With the number of skin cancer cases going up in the past few years, focus on providing early detection and diagnosis is increasing. Melanoma cancer is on a rise owing to the changing environmental conditions and increasing exposure to UV rays. This is driving the demand for rapid diagnostics for early detection of melanoma cancer.

melanoma cancer epidemiology, 2017 canada & eu5 countries

Along with the US, UK is also witnessing a rise in melanoma skin cancer, with around 15,400 new melanoma cancer cases in the UK each year, as per the Cancer Research UK. Two-week wait is the most common way of diagnosing melanoma cancer in the UK. The most common biopsy procedures used in diagnosing melanoma are excisional biopsy, punch biopsy, and incisional biopsy. However, non-invasive test to diagnose melanoma is also gaining popularity across various countries.

Governments Initiatives for Early Detection and Skin Cancer Treatment Drive Adoption

With a rise in melanoma related deaths across various countries, melanoma diagnostics and therapeutics is significantly increasing. Government initiatives, along with the advancement in technology is also driving the growth of melanoma cancer diagnostics. Notable initiatives include,

  • European Skin Care Foundation (ESCF) is strongly focusing on establishing skin cancer centers across Europe. ESCF is also supporting research activities with an emphasis on innovative modalities for diagnosis and treatment.
  • To effectively manage melanoma in New Zealand and Australia, initiatives have been taken by governments in both the countries for early detection and holistic treatment. The Ministry of Health in New Zealand has established National Cancer Program to provide high quality and timely treatment for cancer.
  • The Ministry of Health in New Zealand, in partnership with various institutions, is likely to hold cancer control conference in 2019 to discuss major challenges and identify possible solutions.
  • The Department of Health in Australia review of evidence on effectiveness of public awareness campaigns to increase awareness for need of skin checks among people, with strategies to target high risk groups.

Absence of Accurate Diagnostic Methods to Remain Key Challenge

With rise in cases of melanoma skin cancer across various regions, researchers and scientists are focusing on developing more precise methods of diagnosis along with cost-effectiveness. According to the Agency of Healthcare Research and Quality, cancer is one of the most expensive conditions to treat in the US. Moreover, insurance providers with cost sharing measures are also shifting a huge portion of the medical cost to patients. This has resulted in more out-of-pocket cost for diagnosis and treatment of skin and other types of cancer.

Diagnostic accuracy for melanoma varies significantly with potential financial implications. With advanced diagnostics technologies, the cost of diagnostic procedures, screening, treatment, and medical follow-up is also increasing. According to the study published in the American Journal of Preventive Medicine, in 2007-2011, the average annual cost for skin cancer increased by 126%. Economic burden of skin cancer treatment is significantly increasing with a substantial increase in cost in diagnostics and treatment for melanoma.

Centers for Disease Control and Prevention (CDC) also projects that from 2011 to 2030, annual cost of treating patients suffering from melanoma is likely to increase to $1.6 billion from $457 million. Research presented at 2018 National Cancer Research Institute (NCRI) Conference has also found the rise in the rate of men dying from malignant melanoma. Without accurate and additional prevention measures the incidences is likely to increase in coming years along with the rise in melanoma diagnostics and treatment cost.

For detailed analysis on all the key market factors, request a sample.

Definition

Melanoma is a type of skin cancer developing from pigment-containing cells known as melanocytes. Melanoma cancer diagnostics is to diagnose melanoma with biopsy. During a biopsy, all or the part of mole or growth over the skin is removed to test and analyze the sample. Common biopsy procedures used to diagnose melanoma are punch biopsy, incisional biopsy, and excisional biopsy.

About the Report

The report on the melanoma cancer diagnostics market provides key insights, forecast, and in-depth analysis on the market. The melanoma cancer diagnostics market report also includes macro-economic and micro-economic factors playing an important role in the growth of the market. Market dynamics such as drivers, trends, opportunity, and challenges are also offered in the study.

The melanoma cancer diagnostics market has also been analyzed on the basis of key regions and countries. Qualitative and quantitative analysis of the melanoma cancer diagnostics market is also included in the research study.

Market Structure

Segment-wise analysis of the melanoma cancer diagnostics is highlighted in the report to identify and provide details on the existing market opportunities. The melanoma cancer diagnostics market is segmented on the basis of test type and end user. These segments are further divided into sub-segments to offer better understanding of melanoma cancer diagnostics market.

melanoma cancer diagnostics market taxonomy

Based on the test type, the melanoma cancer diagnostics market is segmented into Fluorescent in Situ Hybridization (FISH) Tests, Immunohistochemical (IHC) Tests, and Comparative Genomic Hybridization (CGH) Tests. On the basis of end-user, the melanoma cancer diagnostics market is segmented into Pathology Laboratories, Hospitals, and Cancer Research Centres.

Additional Questions Answered

The report along with the valuable insights on the melanoma cancer diagnostics market provides answers to some of the important questions on melanoma cancer diagnostics market.

  • Which test type is expected to register the highest growth in the melanoma cancer diagnostics market?
  • What will be the market share of Cancer research Centers in melanoma cancer diagnostics market?
  • Which region is likely to remain lucrative in the melanoma cancer diagnostics market?
  • What factors are driving the growth in the melanoma cancer diagnostics market?

Research Methodology

A robust and unique research methodology is used to offer insights and forecast on the melanoma cancer diagnostics market. In-depth analysis and information provided on the melanoma cancer diagnostics market is based on the primary and secondary research. Interviews with melanoma cancer diagnostics market experts were conducted to identify new growth opportunities and reach qualitative and quantitative conclusions about the growth of the market.

Secondary research was also conducted by using published data and verifying that data with valid sources. Both, primary and secondary research ensure reliability and accuracy of data included in the report.

Request methodology of this Report.

 

1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. Opportunity Assessment
1.4. FACT.MR Analysis and Recommendations
1.5. Wheel of FortuneTM – Opportunity Analysis 

2. Market Introduction
2.1. Market introduction
2.2. Market definition
2.3. Scope of Research

3. Market Dynamics
3.1. Macro - Economic Factors Influencing Demand
3.2. Key Growth Drivers and Impact Analysis
3.3. Industry Challenges and Restraints
3.4. Forecast Factors and Relevance of Impact

4. Key Inclusion
4.1. Melanoma Cancer Diagnostics Pricing Analysis by Test Type 2017
4.2. Melanoma Cancer Country Wise Epidemiology, 2017
4.3. Regulation and Reimbursement Scenario, 2017
4.4. Melanoma Skin Cancer: Global Overview, 2017
4.5. Melanoma Skin Cancer: Survival Rates, 2017
4.6. Melanoma Skin Cancer: Higher Risk Countries Across Globe, 2017

5. Global Melanoma Cancer Diagnostics Market Analysis and Forecast
5.1. Global Melanoma Cancer Diagnostics Market Outlook
       5.1.1. Market Value (US$ Mn) Forecast and Analysis
       5.1.2. Regional Demand Assessment
5.2. Market Value Share by Region
5.3. Global Melanoma Cancer Diagnostics Market Analysis and Forecast, By Test Type
       5.3.1. Market Share Analysis By Test Type
       5.3.2. Y-o-Y Growth Projections By Test type
5.4. Market Size Analysis By Test Type
       5.4.1. Fluorescent In Situ Hybridization (FISH) Tests
       5.4.2. Comparative Genomic Hybridization (CGH) Tests
       5.4.3. Immunohistochemical (IHC) Tests
5.5. Market Attractiveness Analysis By Test Type
5.6. Global Melanoma Cancer Diagnostics Market Analysis and Forecast, By End User
       5.6.1. Market Share Analysis By End User
       5.6.2. Y-o-Y Growth Projections By End User
5.7. Market Size Analysis By End User
       5.7.1. Hospitals
       5.7.2. Pathology Laboratories
       5.7.3. Cancer Research Centres

6. North America Melanoma Cancer Diagnostics Market Analysis
6.1. Introduction
       6.1.1. North America Business Outlook
       6.1.2. North America Melanoma Cancer Diagnostics Market Outlook
6.2. North America Melanoma Cancer Diagnostics Market Outlook
       6.2.1. Market Value (US$ Mn) Forecast and Analysis
       6.2.2. Country Wise Demand Assessment
                6.2.2.1. US 
                6.2.2.2. Canada
6.3. North America Melanoma Cancer Diagnostics Market Analysis by Test Type
       6.3.1. Value(US$ Mn) Forecast by Test Type
       6.3.2. Y-o-Y Growth Comparison by Test Type
6.4. North America Melanoma Cancer Diagnostics Market Analysis by End User
       6.4.1. Value(US$ Mn) Forecast by End User
       6.4.2. Y-o-Y Growth Comparison by End User
6.5. Market Attractiveness Analysis
6.6. Reimbursement scenario

7. Latin America Melanoma Cancer Diagnostics Market Analysis
7.1. Introduction
       7.1.1. Latin America Business Outlook
       7.1.2. Latin America Melanoma Cancer Diagnostics Market Outlook
7.2. Latin America Melanoma Cancer Diagnostics Market Outlook
       7.2.1. Market Value (US$ Mn) Forecast and Analysis
       7.2.2. Country Wise Demand Assessment
                7.2.2.1. Mexico
                7.2.2.2. Brazil
                7.2.2.3. Argentina
7.3. Latin America Melanoma Cancer Diagnostics Market Analysis by Test Type
       7.3.1. Value(US$ Mn) Forecast by Test Type
       7.3.2. Y-o-Y Growth Comparison by Test Type
7.4. Latin America Melanoma Cancer Diagnostics Market Analysis by End User
       7.4.1. Value(US$ Mn) Forecast by End User
       7.4.2. Y-o-Y Growth Comparison by End User
7.5. Market Attractiveness Analysis
7.6. Reimbursement scenario

8. Europe Melanoma Cancer Diagnostics Market Analysis
8.1. Introduction
       8.1.1. Europe Business Outlook
       8.1.2. Europe Melanoma Cancer Diagnostics Market Outlook
8.2. Europe Melanoma Cancer Diagnostics Market Outlook
       8.2.1. Market Value (US$ Mn) Forecast and Analysis
       8.2.2. Country Wise Demand Assessment
                8.2.2.1. Germany
                8.2.2.2. France
                8.2.2.3. UK
                8.2.2.4. Spain
                8.2.2.5. Italy
                8.2.2.6. Belgium
                8.2.2.7. Netherlands
8.3. Europe Melanoma Cancer Diagnostics Market Analysis by Test Type
       8.3.1. Value(US$ Mn) Forecast by Test Type
       8.3.2. Y-o-Y Growth Comparison by Test Type
8.4. Europe Melanoma Cancer Diagnostics Market Analysis by End User
       8.4.1. Value(US$ Mn) Forecast by End User
       8.4.2. Y-o-Y Growth Comparison by End User
8.5. Market Attractiveness Analysis
8.6. Reimbursement scenario

9. CIS & Russia Melanoma Cancer Diagnostics Market Analysis
9.1. Introduction
       9.1.1. CIS & Russia Business Outlook
       9.1.2. CIS & Russia Melanoma Cancer Diagnostics Market Outlook
9.2. CIS & Russia Melanoma Cancer Diagnostics Market Outlook
       9.2.1. Market Value (US$ Mn) Forecast and Analysis
       9.2.2. Country Wise Demand Assessment
                9.2.2.1. CIS
                9.2.2.2. Russia
9.3. CIS & Russia Melanoma Cancer Diagnostics Market Analysis by Test Type
       9.3.1. Value(US$ Mn) Forecast by Test Type
       9.3.2. Y-o-Y Growth Comparison by Test Type
9.4. CIS & Russia Melanoma Cancer Diagnostics Market Analysis by End User
       9.4.1. Value(US$ Mn) Forecast by End User
       9.4.2. Y-o-Y Growth Comparison by End User
9.5. Market Attractiveness Analysis
9.6. Reimbursement scenario

10. Asia Pacific ex. Japan Melanoma Cancer Diagnostics Market Analysis
10.1. Introduction
       10.1.1. Asia Pacific ex. Japan Business Outlook
       10.1.2. Asia Pacific ex. Japan Melanoma Cancer Diagnostics Market Outlook
10.2. Asia Pacific ex. Japan Melanoma Cancer Diagnostics Market Outlook
       10.2.1. Market Value (US$ Mn) Forecast and Analysis
       10.2.2. Country Wise Demand Assessment
                10.2.2.1. China
                10.2.2.2. India
                10.2.2.3. Australia
                10.2.2.4. New Zealand
                10.2.2.5. Thailand
10.3. Asia Pacific ex. Japan Melanoma Cancer Diagnostics Market Analysis by Test Type
       10.3.1. Value(US$ Mn) Forecast by Test Type
       10.3.2. Y-o-Y Growth Comparison by Test Type
10.4. Asia Pacific ex. Japan Melanoma Cancer Diagnostics Market Analysis by End User
       10.4.1. Value(US$ Mn) Forecast by End User
       10.4.2. Y-o-Y Growth Comparison by End User
10.5. Market Attractiveness Analysis
10.6. Reimbursement scenario

11. Japan Melanoma Cancer Diagnostics Market Analysis
11.1. Introduction
       11.1.1. Japan Business Outlook
       11.1.2. Japan Melanoma Cancer Diagnostics Market Outlook
11.2. Japan Melanoma Cancer Diagnostics Market Outlook
       11.2.1. Market Value (US$ Mn) Forecast and Analysis
11.3. Japan Melanoma Cancer Diagnostics Market Analysis by Test Type
       11.3.1. Value(US$ Mn) Forecast by Test Type
       11.3.2. Y-o-Y Growth Comparison by Test Type
11.4. Japan Melanoma Cancer Diagnostics Market Analysis by End User
       11.4.1. Value(US$ Mn) Forecast by End User
       11.4.2. Y-o-Y Growth Comparison by End User
11.5. Market Attractiveness Analysis
11.6. Reimbursement scenario

12. MEA Melanoma Cancer Diagnostics Market Analysis
12.1. Introduction
       12.1.1. MEA Business Outlook
       12.1.2. MEA Melanoma Cancer Diagnostics Market Outlook
12.2. MEA Melanoma Cancer Diagnostics Market Outlook
       12.2.1. Market Value (US$ Mn) Forecast and Analysis
       12.2.2. Country Wise Demand Assessment
                12.2.2.1. South Africa
                12.2.2.2. Turkey
                12.2.2.3. GCC
12.3. MEA Melanoma Cancer Diagnostics Market Analysis by Test Type
       12.3.1. Value(US$ Mn) Forecast by Test Type
       12.3.2. Y-o-Y Growth Comparison by Test Type
12.4. MEA Melanoma Cancer Diagnostics Market Analysis by End User
       12.4.1. Value(US$ Mn) Forecast by End User
       12.4.2. Y-o-Y Growth Comparison by End User
12.5. Market Attractiveness Analysis
12.6. Reimbursement scenario

13. Assumptions and Acronyms Used

14. Research Methodology

Table 01: US Average Test Price (US$), By Test Type
Table 02: Canada Average Test Price (US$), By Test Type
Table 03: Germany Average Test Price (US$), By Test Type
Table 04: France Average Test Price (US$), By Test Type
Table 05: U.K. Average Test Price (US$), By Test Type
Table 06: Spain Average Test Price (US$), By Test Type
Table 07: Italy Average Test Price (US$), By Test Type
Table 08: Australia Average Test Price (US$), By Test Type
Table 09: Melanoma Cancer Diagnostics Market: Regulation and Reimbursement Scenario
Table 10: Global Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Region
Table 11: Global Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Test Type
Table 12: Global Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By End User
Table 13: North America Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country
Table 14: North America Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Test Type
Table 15: North America Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By End User
Table 16: Latin America Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country
Table 17: Latin America Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Test Type
Table 18: Latin America Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By End User
Table 19: Europe Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country
Table 20: Europe Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Test Type
Table 21: Europe Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By End User
Table 22: CIS & Russia Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country
Table 23: CIS & Russia Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Test Type
Table 24: CIS & Russia Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By End User
Table 25: APEJ Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country
Table 26: APEJ Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Test Type
Table 27: APEJ Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By End User
Table 28: Japan Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Test Type
Table 29: Japan Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By End User
Table 30: Middle East & Africa Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country
Table 31: Middle East & Africa Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Test Type
Table 32: Middle East & Africa Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By End User

Figure 01: melanoma cancer diagnostics Market Value Share By Region (2018)
Figure 02: Global Melanoma Cancer Diagnostics Market Share, By Region(2017)
Figure 03: Global Melanoma Cancer Diagnostics Market Share, By Test Type (2017)
Figure 04: Global Melanoma Cancer Diagnostics Market Share, By End User (2017)
Figure 05: Global Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 06: Global Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 07: Global Melanoma Cancer Diagnostics Market Attractiveness Analysis, By Region
Figure 08: Global Melanoma Cancer Diagnostics Market Value Share Analysis, By Region, 2017 & 2028
Figure 09: Global Melanoma Cancer Diagnostics Market Attractiveness Analysis, By Test Type
Figure 10: Global Melanoma Cancer Diagnostics Market Value Share Analysis, By Test Type, 2017 & 2028
Figure 11: Global Melanoma Cancer Diagnostics Market Attractiveness Analysis, By End User
Figure 12: Global Melanoma Cancer Diagnostics Market Value Share Analysis, By End User, 2017 & 2028
Figure 13: North America Melanoma Cancer Diagnostics Market, Snapshot
Figure 14: North America Melanoma Cancer Diagnostics Market Value Share, by Country (2017)
Figure 15: North America Melanoma Cancer Diagnostics Market Value Share, by Test Type (2017)
Figure 16: North America Melanoma Cancer Diagnostics Market Value Share, by End User (2017)
Figure 17: North America Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 18: North America Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 19: US Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 20: US Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 21: Canada Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 22: Canada Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 23: North America Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Fluorescent In Situ Hybridization (FISH) Tests
Figure 24: North America Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Fluorescent In Situ Hybridization (FISH) Tests
Figure 25: North America Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Comparative Genomic Hybridization (CGH) Tests
Figure 26: North America Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Comparative Genomic Hybridization (CGH) Tests
Figure 27: North America Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Immunohistochemical (IHC) Tests
Figure 28: North America Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Immunohistochemical (IHC) Tests
Figure 29: North America Melanoma Cancer Diagnostics Market Attractiveness Analysis, By Country
Figure 30: North America Melanoma Cancer Diagnostics Market Attractiveness Analysis, By Test Type
Figure 31: North America Melanoma Cancer Diagnostics Market Attractiveness Analysis, By End User
Figure 32: Latin America Melanoma Cancer Diagnostics Market, Snapshot
Figure 33: Latin America Melanoma Cancer Diagnostics Market Value Share, by Country (2017)
Figure 34: Latin America Melanoma Cancer Diagnostics Market Value Share, by Test Type (2017)
Figure 35: Latin America Melanoma Cancer Diagnostics Market Value Share, by End User (2017)
Figure 36: Latin America Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 37: Latin America Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 38: Mexico Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 39: Mexico Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 40: Brazil Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 41: Brazil Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 42: Argentina Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 43: Argentina Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 44: Latin America Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Fluorescent In Situ Hybridization (FISH) Tests
Figure 45: Latin America Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Fluorescent In Situ Hybridization (FISH) Tests
Figure 46: Latin America Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Comparative Genomic Hybridization (CGH) Tests
Figure 47: Latin America Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Comparative Genomic Hybridization (CGH) Tests
Figure 48: Latin America Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Immunohistochemical (IHC) Tests
Figure 49: Latin America Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Immunohistochemical (IHC) Tests
Figure 50: Latin America Melanoma Cancer Diagnostics Market Attractiveness Analysis, By Country
Figure 51: Latin America Melanoma Cancer Diagnostics Market Attractiveness Analysis, By Test Type
Figure 52: Latin America Melanoma Cancer Diagnostics Market Attractiveness Analysis, By End User
Figure 53: Europe Melanoma Cancer Diagnostics Market, Snapshot
Figure 54: Europe Melanoma Cancer Diagnostics Market Value Share, by Country (2017)
Figure 55: Europe Melanoma Cancer Diagnostics Market Value Share, by Test Type (2017)
Figure 56: Europe Melanoma Cancer Diagnostics Market Value Share, by End User (2017)
Figure 57: Europe Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 58: Europe Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 59: Germany Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 60: Germany Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 61: France Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 62: France Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 63: UK Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 64: UK Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 65: Spain Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 66: Spain Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 67: Italy Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 68: Italy Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 69: Belgium Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 70: Belgium Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 71: Netherlands Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 72: Netherlands Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 73: Europe Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Fluorescent In Situ Hybridization (FISH) Tests
Figure 74: Europe Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Fluorescent In Situ Hybridization (FISH) Tests
Figure 75: Europe Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Comparative Genomic Hybridization (CGH) Tests
Figure 76: Europe Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Comparative Genomic Hybridization (CGH) Tests
Figure 77: Europe Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Immunohistochemical (IHC) Tests
Figure 78: Europe Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Immunohistochemical (IHC) Tests
Figure 79: Europe Melanoma Cancer Diagnostics Market Attractiveness Analysis, By Country
Figure 80: Europe Melanoma Cancer Diagnostics Market Attractiveness Analysis, By Test Type
Figure 81: Europe Melanoma Cancer Diagnostics Market Attractiveness Analysis, By End User
Figure 82: CIS & Russia Melanoma Cancer Diagnostics Market, Snapshot
Figure 83: CIS & Russia Melanoma Cancer Diagnostics Market Value Share, by Country (2017)
Figure 84: CIS & Russia Melanoma Cancer Diagnostics Market Value Share, by Test Type (2017)
Figure 85: CIS & Russia Melanoma Cancer Diagnostics Market Value Share, by End User (2017)
Figure 86: CIS & Russia Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 87: CIS & Russia Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 88: CIS Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 89: CIS Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 90: Russia Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 91: Russia Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 92: CIS & Russia Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Fluorescent In Situ Hybridization (FISH) Tests
Figure 93: CIS & Russia Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Fluorescent In Situ Hybridization (FISH) Tests
Figure 94: CIS & Russia Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Comparative Genomic Hybridization (CGH) Tests
Figure 95: CIS & Russia Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Comparative Genomic Hybridization (CGH) Tests
Figure 96: CIS & Russia Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Immunohistochemical (IHC) Tests
Figure 97: CIS & Russia Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Immunohistochemical (IHC) Tests
Figure 98: CIS & Russia Melanoma Cancer Diagnostics Market Attractiveness Analysis, By Country
Figure 99: CIS & Russia Melanoma Cancer Diagnostics Market Attractiveness Analysis, By Test Type
Figure 100: CIS & Russia Melanoma Cancer Diagnostics Market Attractiveness Analysis, By End User
Figure 101: APEJ Melanoma Cancer Diagnostics Market, Snapshot
Figure 102: APEJ Melanoma Cancer Diagnostics Market Value Share, by Country (2017)
Figure 103: APEJ Melanoma Cancer Diagnostics Market Value Share, by Test Type (2017)
Figure 104: APEJ Melanoma Cancer Diagnostics Market Value Share, by End User (2017)
Figure 105: APEJ Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 106: APEJ Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 107: China Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 108: China Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 109: India Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 110: India Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 111: Australia Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 112: Australia Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 113: New Zealand Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 114: New Zealand Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 115: Thailand Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 116: Thailand Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 117: APEJ Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Fluorescent In Situ Hybridization (FISH) Tests
Figure 118: APEJ Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Fluorescent In Situ Hybridization (FISH) Tests
Figure 119: APEJ Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Comparative Genomic Hybridization (CGH) Tests
Figure 120: APEJ Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Comparative Genomic Hybridization (CGH) Tests
Figure 121: APEJ Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Immunohistochemical (IHC) Tests
Figure 122: APEJ Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Immunohistochemical (IHC) Tests
Figure 123: APEJ Melanoma Cancer Diagnostics Market Attractiveness Analysis, By Country
Figure 124: APEJ Melanoma Cancer Diagnostics Market Attractiveness Analysis, By Test Type
Figure 125: APEJ Melanoma Cancer Diagnostics Market Attractiveness Analysis, By End User
Figure 126: Japan Melanoma Cancer Diagnostics Market, Snapshot
Figure 127: Japan Melanoma Cancer Diagnostics Market Value Share, by End User (2017)
Figure 128: Japan Melanoma Cancer Diagnostics Market Value Share, by Test Type (2017)
Figure 129: Japan Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 130: Japan Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 131: Japan Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Fluorescent In Situ Hybridization (FISH) Tests
Figure 132: Japan Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Fluorescent In Situ Hybridization (FISH) Tests
Figure 133: Japan Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Comparative Genomic Hybridization (CGH) Tests
Figure 134: Japan Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Comparative Genomic Hybridization (CGH) Tests
Figure 135: Japan Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Immunohistochemical (IHC) Tests
Figure 136: Japan Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Immunohistochemical (IHC) Tests
Figure 137: Japan Melanoma Cancer Diagnostics Market Attractiveness Analysis, By End User
Figure 138: Japan Melanoma Cancer Diagnostics Market Attractiveness Analysis, By Test Type
Figure 139: Middle East & Africa Melanoma Cancer Diagnostics Market, Snapshot
Figure 140: Middle East & Africa Melanoma Cancer Diagnostics Market Value Share, by Country (2017)
Figure 141: Middle East & Africa Melanoma Cancer Diagnostics Market Value Share, by Test Type (2017)
Figure 142: Middle East & Africa Melanoma Cancer Diagnostics Market Value Share, by End User (2017)
Figure 143: Middle East & Africa Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 144: Middle East & Africa Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 145: South Africa Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 146: South Africa Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 147: Turkey Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 148: Turkey Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 149: GCC Countries Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017
Figure 150: GCC Countries Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 151: Middle East & Africa Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Fluorescent In Situ Hybridization (FISH) Tests
Figure 152: Middle East & Africa Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Fluorescent In Situ Hybridization (FISH) Tests
Figure 153: Middle East & Africa Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Comparative Genomic Hybridization (CGH) Tests
Figure 154: Middle East & Africa Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Comparative Genomic Hybridization (CGH) Tests
Figure 155: Middle East & Africa Melanoma Cancer Diagnostics Market Size (US$ Mn) Analysis, 2013–2017, By Immunohistochemical (IHC) Tests
Figure 156: Middle East & Africa Melanoma Cancer Diagnostics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Immunohistochemical (IHC) Tests
Figure 157: Middle East & Africa Melanoma Cancer Diagnostics Market Attractiveness Analysis, By Country
Figure 158: Middle East & Africa Melanoma Cancer Diagnostics Market Attractiveness Analysis, By Test Type
Figure 159: Middle East & Africa Melanoma Cancer Diagnostics Market Attractiveness Analysis, By End User

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Benefits of Becoming a Fact.MR Client

  • Access to our global market coverage
  • Periodic updates on your sector
  • Exclusive discounts and offers
  • Greater flexibility for customization
  • Quick-research assistance for ad-hoc needs
  • Access to credible insights Fact.MR analyst interactions
  • Access to Fact.MR tools and research to fuel strategy development